Classification of Mild Cognitive Impairment and Alzheimer's Disease Using Manual Motor Measures

Vincent Koppelmans1,2, Marit F L Ruitenberg3,4, Sydney Y Schaefer5

  • 1Department of Psychiatry, University of Utah, Salt Lake City, Utah, USA.

PubMed
Abstract

Insights

Psychomotor speed is reduced in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Manual motor tasks show potential for classifying AD, but not MCI, and correlate with Alzheimer's biomarkers.

Area of Science:

  • Neurology
  • Neuroscience
  • Biomarkers

Background:

  • Mild cognitive impairment (MCI) and Alzheimer's disease (AD) are associated with manual motor deficits.
  • Specific motor impairments, their neuropathological basis, and classification potential remain unclear.

Purpose of the Study:

  • To investigate if manual motor strength, dexterity, and speed are affected in MCI and AD.
  • To determine the relationship between motor function and AD biomarkers.
  • To assess the utility of manual motor function for classifying MCI and AD.

Main Methods:

  • Fifty-three cognitively normal (CN), 33 amnestic MCI, and 28 AD subjects performed five manual motor tasks.
  • Analyses included group differences, correlations with AD biomarkers (amyloid β PET, hippocampal volume, APOE ε4), and machine learning classification.
  • Manual motor measures included grip force, Trail Making Test A, spiral tracing, finger tapping, and a simulated feeding task.

Main Results:

  • Amnestic MCI and AD groups showed slower psychomotor speed compared to CN.
  • AD subjects exhibited weaker dominant hand grip strength than CN subjects.
  • Motor performance correlated with amyloid β deposition and, for psychomotor speed, with hippocampal volume.

Conclusions:

  • Psychomotor speed is impaired in MCI and AD, while grip strength and spiral tracing are preserved.
  • Motor deficits are linked to amyloid β deposition and brain atrophy, suggesting later-stage disease involvement.
  • Manual motor measures show promise for AD classification and could enhance clinical trials.